Abstract | PURPOSE: To report the results of the Malignant Mesenchymal Tumors studies ( MMT 84 and 89) of the International Society of Pediatric Oncology (SIOP) in males with nonmetastatic paratesticular rhabdomyosarcoma. PATIENTS AND METHODS: RESULTS: Median age at diagnosis was 65 months. Thirty-one tumors were larger than 5 cm, and 13 males were older than 10 years with a tumor larger than 5 cm. At a median follow-up of 7 years, 87 patients were alive; 79 were in first complete remission and eight were in second complete remission. Relapse occurred in 16 patients (17%). At 5 years, the overall survival (OS) rate was 92%, with an event-free survival (EFS) rate of 82%. OS and EFS were significantly worse for males with tumors greater than 5 cm and for males older than 10 years at diagnosis. CONCLUSION: Males with paratesticular RMS have an excellent prognosis except for a selected group of patients older than 10 years or with tumor greater than 5 cm. Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.
|
Authors | Richard J Stewart, Hélène Martelli, Odile Oberlin, Annie Rey, Nathalie Bouvet, Richard D Spicer, Jan Godzinski, Michael C G Stevens, International Society of Pediatric Oncology |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 5
Pg. 793-8
(Mar 01 2003)
ISSN: 0732-183X [Print] United States |
PMID | 12610176
(Publication Type: Journal Article)
|
Chemical References |
- Dactinomycin
- Vincristine
- Ifosfamide
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Child, Preschool
- Combined Modality Therapy
- Dactinomycin
(therapeutic use)
- Disease-Free Survival
- Humans
- Ifosfamide
(therapeutic use)
- Infant
- Lymph Node Excision
- Male
- Mesenchymoma
(drug therapy, pathology, surgery)
- Neoplasm Recurrence, Local
(drug therapy, surgery)
- Neoplasm Staging
- Rhabdomyosarcoma
(drug therapy, pathology, surgery)
- Salvage Therapy
- Survival Rate
- Testicular Neoplasms
(drug therapy, pathology, surgery)
- Treatment Outcome
- Vincristine
(therapeutic use)
|